Analysts’ Weekly Ratings Updates for Nevro (NVRO)

A number of firms have modified their ratings and price targets on shares of Nevro (NYSE: NVRO) recently:

• 12/18/2024 – Nevro had its price target lowered by analysts at Truist Financial Co. from $7.00 to $4.70. They now have a “hold” rating on the stock.
• 12/11/2024 – Nevro had its price target lowered by analysts at Citigroup Inc. from $6.00 to $5.00. They now have a “neutral” rating on the stock.
• 12/11/2024 – Nevro had its price target lowered by analysts at Wells Fargo & Company from $5.00 to $4.00. They now have an “equal weight” rating on the stock.
• 12/9/2024 – Nevro had its price target lowered by analysts at Canaccord Genuity Group Inc. from $7.00 to $4.00. They now have a “hold” rating on the stock.
• 12/3/2024 – Nevro is now covered by analysts at Wells Fargo & Company. They set an “equal weight” rating and a $5.00 price target on the stock.
• 12/2/2024 – Nevro was downgraded by analysts at Morgan Stanley from an “equal weight” rating to an “underweight” rating. They now have a $4.00 price target on the stock, down previously from $9.00.
• 11/19/2024 – Nevro was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 11/12/2024 – Nevro had its price target lowered by analysts at Piper Sandler from $7.00 to $6.00. They now have an “underweight” rating on the stock.
• 11/12/2024 – Nevro had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $7.00 price target on the stock.
• 11/12/2024 – Nevro had its price target raised by analysts at Robert W. Baird from $5.00 to $6.00. They now have a “neutral” rating on the stock.
• 11/12/2024 – Nevro had its “market perform” rating reaffirmed by analysts at JMP Securities.
• 11/12/2024 – Nevro had its price target lowered by analysts at Canaccord Genuity Group Inc. from $8.00 to $7.00. They now have a “hold” rating on the stock.
• 11/9/2024 – Nevro was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 11/1/2024 – Nevro was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 10/24/2024 – Nevro was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.

Nevro Stock Up 5.3 %

NYSE:NVRO traded up $0.19 on Friday, hitting $3.78. 111,299 shares of the company’s stock traded hands, compared to its average volume of 558,788. Nevro Corp. has a 1 year low of $3.52 and a 1 year high of $22.52. The company has a current ratio of 5.02, a quick ratio of 3.76 and a debt-to-equity ratio of 0.67. The company has a market cap of $141.64 million, a PE ratio of -2.00 and a beta of 0.84. The firm has a 50-day moving average price of $4.68 and a 200-day moving average price of $6.35.

Nevro (NYSE:NVRO) last released its earnings results on Monday, November 11th. The medical equipment provider reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.40. The firm had revenue of $96.60 million during the quarter, compared to analysts’ expectations of $93.09 million. Nevro had a negative net margin of 16.54% and a negative return on equity of 23.52%. The business’s quarterly revenue was down 7.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.65) EPS. Equities analysts anticipate that Nevro Corp. will post -2.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Nevro

A number of hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC grew its stake in shares of Nevro by 1,788.8% in the second quarter. Nisa Investment Advisors LLC now owns 6,932 shares of the medical equipment provider’s stock valued at $58,000 after buying an additional 6,565 shares in the last quarter. Canada Pension Plan Investment Board boosted its stake in Nevro by 345.8% in the second quarter. Canada Pension Plan Investment Board now owns 10,700 shares of the medical equipment provider’s stock valued at $90,000 after buying an additional 8,300 shares in the last quarter. Virtu Financial LLC acquired a new stake in Nevro in the third quarter valued at approximately $63,000. Intech Investment Management LLC acquired a new position in shares of Nevro in the third quarter valued at approximately $69,000. Finally, SG Americas Securities LLC bought a new stake in Nevro during the 3rd quarter worth approximately $71,000. Institutional investors and hedge funds own 95.52% of the company’s stock.

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.